Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2109556 | 1.00 | CA1 (0.39) | CA1CA2ALDH1A1EPHX1ACHE | |
| SCHEMBL93215 | 1.00 | CA1 (0.39) | CA1CA2ALDH1A1EPHX1ACHE | |
| SCHEMBL2109539 | 1.00 | CA1 (0.39) | CA1CA2ALDH1A1EPHX1ACHE | |
| SCHEMBL9431 | 1.00 | — | — | |
| SCHEMBL302897 | 1.00 | CA1 (0.39) | CA1CA2ALDH1A1EPHX1ACHE | |
| SCHEMBL93249 | 1.00 | CA1 (0.39) | CA1CA2ALDH1A1EPHX1ACHE | |
| SCHEMBL2110868 | 1.00 | CA1 (0.39) | CA1CA2ALDH1A1EPHX1ACHE | |
| SCHEMBL2108202 | 1.00 | CA1 (0.39) | CA1CA2ALDH1A1EPHX1ACHE | |
| SCHEMBL2109113 | 1.00 | CA1 (0.39) | CA1CA2ALDH1A1EPHX1ACHE | |
| SCHEMBL93204 | 1.00 | CA1 (0.39) | CA1CA2ALDH1A1EPHX1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112209967-A | Chiral spiro monophosphine-oxazoline ligand and preparation method thereof | 瑞博(杭州)医药科技有限公司 | 2021-01-12 | — | — | CN | claimed |
| CN-111909206-A | Chiral spiro monophosphine ligand and preparation method thereof | 浙江瑞博制药有限公司 | 2020-11-10 | — | — | CN | claimed |
| CN-112512529-B | Cyclopentenepurine derivative or salt thereof | 富士胶片株式会社 | 2024-06-18 | — | — | CN | disclosed |
| EP-3831388-B1 | CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF FOR USE IN SUPPRESSING ADENOVIRUS | FUJIFILM CORP (JP) | 2024-02-28 | — | — | EP | disclosed |
| CN-113993719-B | Trisulfide compound | 住友化学株式会社 | 2024-01-02 | — | — | CN | disclosed |
| CN-109709770-B | Resin composition, dry film and method for producing same, method for producing resist film and substrate, method for producing plated molded article, and mercapto compound | 东京应化工业株式会社 | 2023-11-24 | — | — | CN | disclosed |
| US-20230295202-A1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2023-09-21 | — | — | US | disclosed |
| US-11760864-B2 | Trisulfide compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-09-19 | — | — | US | disclosed |
| EP-3831836-B1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORP (JP) | 2023-09-06 | — | — | EP | disclosed |
| US-20230229084-A1 | CHEMICALLY AMPLIFIED PHOTOSENSITIVE COMPOSITION, PHOTOSENSITIVE DRY FILM, PRODUCTION METHOD OF SUBSTRATE HAVING TEMPLATE FOR PLATING, AND PRODUCTION METHOD OF PLATED ARTICLE | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-07-20 | — | — | US | disclosed |
| US-11692088-B2 | Rubber composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-07-04 | — | — | US | disclosed |
| EP-0436902-A1 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-17 | — | — | EP | disclosed |
| US-4983609-A | Anticancer agents | OTSUKA PHARMACEUTICAL (JP) | 1991-01-08 | — | — | US | disclosed |
| US-4933355-A | ALDOSE REDUCTASE INHIBITORS | SANKYO COMPANY LIMITED (JP) | 1990-06-12 | — | — | US | disclosed |
| EP-0337819-A1 | Thiazole derivatives, their preparation and their use in the treatment of diabetes complications | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
| US-4864021-A | ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
| US-4859759-A | Siloxane containing benzotriazolyl/tetraalkylpiperidyl substituent | KIMBERLY-CLARK CORPORATION (US) | 1989-08-22 | — | — | US | disclosed |
| EP-0323441-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-05 | — | — | EP | disclosed |
| EP-0180897-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295202-A1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | SLC28A1, SLC20A1, SLC29A1 | CA1 1860/4885CA2 1567/4885ALDH1A1 504/4885 |
| US-11760864-B2 | Trisulfide compound | TST, TMT1A, SULT1A1 | CA1 2459/4885CA2 3632/4885ALDH1A1 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.